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Introduction 
Mesothelioma is a rare form of cancer arising from a monolayer of mesothelial cells that form 
the lining of the internal body cavities and organs, with the vast majority of cases arising from 
the pleura (65-80%), less commonly from the peritoneum (10-30%), and rarely from the 
pericardium and tunica vaginalis testis (1-2%).(1-3) Malignant mesothelioma (MM) is 
aggressive and is known to be locally invasive and have a propensity for metastasis to distant 
organs, rarely including metastasizing to the skin. Cutaneous involvement by MM can occur 
through three main routes: regional spread via lymphatics, direct extension within surgical scars, 
and distant metastasis via hematogenous spread.(4, 5) The most common route, direct extension 
in the form of needle track metastasis (NTM), can occur after placement of intraperitoneal 
catheters in the treatment of MM or through the contamination of surgical sites.(5-10) Few 
reports have noted true cutaneous metastasis of MM, with less than twenty cases found in the 
literature.(1, 2, 4, 6-9, 11-27)  
 
Case Report 
A 75-year-old retired automobile mechanic who specialized in brake repair presented to the 
Emergency Department with rapidly progressive dyspnea. A chest radiograph was performed, 
which showed a large left-sided pleural effusion. Evaluation of thoracentesis fluid showed 
reactive mesothelial cells without evidence of malignancy. Over the next few months, he 
experienced increasing dyspnea, hemoptysis, anorexia, and persistent hemorrhagic pleural 
effusions. A video-assisted thoracoscopic surgery (VATS) was performed, and multiple biopsies 
showed marked pleural thickening with a mixed infiltrate of tumor nests and necrotic debris. 
Immunohistochemical stains were positive for cytokeratin (CK) 5/6, CK7, Calretinin, D2-40 
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(podoplanin), p53, GLUT-1, with focal positivity of MOC-31, and negative for thyroid 
transcription factor (TTF)-1, CK20, caudal-related homeobox gene 2 (CDX2), BerEP4, and 
Napsin A (Fig. 1). The diagnosis of malignant mesothelioma of the pleura, stage II, was made. 
Due to his significant co-morbidities, he was not a candidate for systemic chemotherapy. 
Four months later, he presented with a new single firm, pink cutaneous nodule measuring 
6 x 8 mm on his upper back (Fig. 2). A shave biopsy was performed, which revealed a 
reasonably well-circumscribed nodular dermal proliferation of atypical epithelioid tumor cells 
forming pseudoglandular structures with numerous mitoses. The well-circumscribed and nodular 
growth pattern within the dermis as well as lack of surgical scars in the surrounding area favored 
metastasis over direct extension.  Immunohistochemical stains showed immunoreactivity for 
CK5/6, CK7, Calretinin, and D2-40 and negative staining for TTF-1, CK20, GLUT-1, and 
prostate-specific antigen (PSA) (Fig. 3). The collective findings supported a diagnosis of 
epithelioid malignant mesothelioma metastatic to the skin. Unfortunately, the patient succumbed 
to his disease within a week following his biopsy.   
 
Discussion 
The results of a literature search of cases of cutaneous metastasis of malignant mesothelioma are 
summarized in Table 1.(2, 4, 6-9, 11, 12, 17-21, 23-27) There were nineteen previously reported 
cases of MM metastatic to the skin, three of which predated the availability of 
immunohistochemical stains. We excluded cases in which the cutaneous presentation was due to 
direct extension or regional spread. Importantly, as the umbilicus is an embryological remnant of 
the vitelline duct and retains a connection to the peritoneal cavity (22), we excluded cases of 
umbilical presentations of MM as we consider it to be a direct extension.(14, 16, 22) The average 
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age at presentation of cutaneous metastasis was 56.5 years (range: 25-77). Excluding one outlier 
(12), the average time from original diagnosis of MM to presentation of cutaneous metastasis 
was six months, with seven individuals receiving their diagnosis of MM at or shortly after the 
time of their cutaneous biopsy. MM primary to the pleura accounted for 85% of reported cases of 
cutaneous metastases, and peritoneal MM accounted for 15% of reported cases. The most 
commonly reported site of cutaneous metastasis was the face, followed by the scalp and chest. 
All peritoneal MM cases were of the epithelioid subtype. Approximately 60% of cases of pleural 
MM were of the epithelioid subtype, 23% were of the sarcomatoid subtype, and 17% were of the 
biphasic subtype. The majority of reports demonstrated positive staining with calretinin, 
cytokeratins (especially CK 5/6 and CK 7), vimentin, epithelial membrane antigen (EMA), 
thrombomodulin, HMBE-1, and Wilms’ Tumor (WT)-1. Commonly used negative stains 
included carcinoembryonic antigen (CEA), S100, TTF-1, Leu M1, Factor VIIIRA, cluster of 
differentiation (CD)-31, CD34, B72.3, and human melanoma black (HMB)-45.  
The diagnosis of MM can be challenging for several reasons, including delayed and non-
specific presentation, relative paucity of sensitive diagnostic techniques, and histologic similarity 
to other neoplasms. Primary MM has a very long latency period, often presenting up to four or 
five decades post-exposure, and is linked to asbestos exposure (including automobile brakes, 
which formerly contained asbestos) in up to 90% of cases of pleural MM.(1, 5, 6, 20, 28-31) Due 
to the delay from exposure to onset of symptoms, the disease is typically far progressed at the 
time of diagnosis, with metastases typically appearing at a late stage of the disease.(3, 9, 25, 32, 
33) Additionally, diagnosis can be delayed because the symptoms for both pleural and peritoneal 
MM are vague and non-specific, including chest pain, dyspnea for pleural MM and abdominal 
pain, weight loss, and increased abdominal girth for peritoneal MM.(1, 3, 20, 26) Recurrent 
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pleural effusions and ascites are common in pleural and peritoneal MM, respectively. However, 
sampling of body cavity fluid cytology is oftentimes non-diagnostic, with reports estimating the 
sensitivity to be between 33 and 84%.(21, 32) Clinically, cutaneous metastases of MM can 
appear as violaceous nodules or papules (as is seen in the present case), erythematous eruptions, 
or inflammatory and infiltrative plaques.(5, 9)  
There are three main histologic subtypes of MM: epithelioid (60%), sarcomatoid (10-
20%), and biphasic or mixed (20-30%), which has both epithelioid and sarcomatoid 
components.(3, 5, 8, 29) The epithelioid subtype is comprised of trabecular cords of cuboidal, 
oval, or polygonal cells that are usually clumped together with visible, elongated nuclei and 
abundant eosinophilic cytoplasm and may have various secondary patterns, including 
tubulopapillary, micropapillary, acinar, adenoid cystic, clear cell, signet ring, solid, small and 
large cell patterns, and pleomorphic.(1, 5) The sarcomatoid subtype, the least common yet most 
aggressive subtype, is comprised of spindle cells arranged in fascicles with enlarged and 
elongated nuclei, which may have desmoplastic, lymphohistiocytic, fibrosarcomatous, 
chondrosarcomatous, osteosarcomatous, and malignant fibrous histiocytoma-like secondary 
patterns.(5, 34, 35) MM can be difficult to diagnose histologically, as the tumor can resemble 
features of benign reactive mesothelial proliferations, metastatic adenocarcinoma (especially 
neoplasms from the gastrointestinal tract, breast, lung, prostate, kidney, or thyroid), sarcoma 
(especially epithelioid angiosarcoma, which can develop from prior radiation exposure), 
lymphoma, and melanoma (adenoid or pseudopapillary subtypes).(1, 6-9, 12, 20, 23, 24, 26, 28) 
As such, immunohistochemistry plays a pivotal role in diagnosis. However, no specific unique 
immunohistochemical or genetic marker has been elucidated to allow for prompt, efficient 
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diagnosis. Therefore, the diagnosis of MM is typically one of exclusion and relies heavily on 
patterns of positive and negative stains.(3, 28, 35)  
Calretinin is considered to be one of the most specific stains for MM, as it strongly and 
diffusely stains both the nucleus and cytoplasm, is frequently expressed in all histologic subtypes 
of MM, and stains positively in less than ten percent of adenocarcinoma.(1, 5, 12, 36, 37) Other 
less specific markers for MM are considered to be WT1, CK 5/6, thrombomodulin, and HBME-
1.(5, 24, 27) Pertinent negative stains for MM include CEA, CA-125, Leu M1 (CD15), BerEP4, 
MOC-31, TTF-1, B72.3, which stain positively in adenocarcinoma, S100 and HMB-45, which 
stain positively in melanoma, Factor VIII, vimentin, and CD31, which stain positively in 
angiosarcoma, and PSA, which stains positively in prostatic adenocarcinoma.(5, 21, 23, 24, 28) 
Current recommendations for diagnosing MM suggest initial screening panels to include positive 
staining for at least two MM markers (such as calretinin, WT1, CK5/6) and negative staining for 
at least two carcinoma markers (such as CEA, Leu M1, BerEP4, TTF-1).(28, 38) More recent 
research has shown promising results using fluorescence in situ hybridization (FISH) analysis to 
detect homozygous deletion of p16 and immunohistochemistry to detect loss of nuclear staining 
of BRCA1-associated protein 1 (BAP1), independently or in combination, for difficult cases of 
MM.(38-40) This is especially useful in differentiating between malignant pleural mesothelioma 
and benign reactive mesothelial hyperplasia, which have cytologic and histologic similarities.(39, 
41) 
Though not approved for use at present, two serum markers, serum mesothelin-related 
protein (SRMP) and osteopontin, have been proposed to aid in diagnosis and monitor 
progression of MM. (26, 31, 42-44). Diagnosis can be challenging, but a thorough workup 
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including histologic, immunohistochemical, and molecular investigations, in combination with 
clinical and radiologic correlation, can aid in diagnosis.
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Fig. 1. Hematoxylin and eosin staining of the pleural biopsy revealed marked thickening and a fibroblastic 
reaction to infiltrative tumor nests and pseudoglandular structures (A: x40). The tumor cells are mildly 
pleomorphic with increased mitotic activity (B and C: x100 and x200). Immunohistochemical staining 
showed positivity for calretinin (D: x200), CK 5/6 (E: x200), and CK7 (F: x200).  
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Fig. 2.  A clinical image shows a single firm, pink cutaneous papule on the upper trunk.  
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Fig. 3. Hematoxylin and eosin staining of the cutaneous nodule shows a fairly well-circumscribed nodular 
proliferation of epithelioid cells within the dermis (A: x40). The tumor forms pseudoglandular structures with 
cytologic atypia and mitoses (B and C: x200 and x400). Immunohistochemical stains with positive results 
include calretinin (D: x200), CK 5/6 (E: x200), and CK7 (F: x200).  
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Case Year of 
Publication, 
Reference
Age (years) 
at 
Presentation
/ Gender
Location of 
cutaneous 
mets
Time from 
original 
diagnosis of 
MM to met 
presentation
Positive Stains Negative Stains Type of 
Mesotheliom
a
Subtype of 
Cutaneous 
Metastasis
Treatment Outcome/follow up
1 1968 11 65/M Scalp 2 mths Not Reported Not Reported Pleural Sarcomatoi Not Reported Not Reported
2 1980 17 50/M Chest, face 16 mths, 21 
mths
Not Reported Not Reported Pleural Biphasic* Chemotherapy 
(cyclophosphamide, 
doxorubicin, MTX x4 
mths), Radiation
Deceased within 23 mths
3 1983 24 54/M Neck, 
thorax, 
flank, 
abdomen
3 mths Not Reported Not Reported Peritoneal Epithelioid* Chemotherapy (4 
cycles: 
Cycles 1 & 2: 
vincristine, 
dacarbazine, 
cyclophosphamide
Cycle 3: doxorubicin, 
dacarbazine, 
cyclophosphamide
Cycle 4: (2 doses): MTX, 
Deceased within 11 mths
4 1992 7 60/M Cheek At time of 
biopsy
Cytokeratin, 
Vimentin, EMA, 
Orthokeratin
Leu M1, CEA, 
S100, Factor 
VIIIRA, UE
Pleural Epithelioid Not Reported Deceased shortly after 
biopsy
5 1997 9 50/M Chest wall 12 mths Cytokeratin 
(AE1/AE3, 
MNF116, CAM 
5.2), EMA
Leu M1 (CD15), 
CEA, CD34, 
Factor VIIIRA, 
UE
Pleural Epithelioid Radiation Not Reported
6 2003 6 64/M Lip, flank, 
pubis, calf
9 mths Calretinin, 
Cytokeratin (CK19 
& AE1/AE3), 
HBME-1
Leu M1, CEA, 
BerEP4, B72.3, 
S100,     HMB-
45, MART-1, 
Pleural Epithelioid Radiation Not Reported
7 2003 21 64/M Chin At time of 
biopsy
Cytokeratin 
(MNF116)
Not Reported Pleural Sarcomatoi
d
Radiation Not Reported
8 2005 4 25/F Back, upper 
& lower 
extremities
3 mths Not Reported Not Reported Pleural Sarcomatoi
d
Surgery, chemotherapy 
(6 cycles), radiation
Progressive disease on 
subsequent imaging
9 2006 23 53/M Flank At time of 
biopsy
Calretinin, 
Cytokeratins 
(MNF116), CK5/6 
(weak),  CK7
CEA, CD31, 
CD34, S100, 
CK20
Pleural Epithelioid Chemotherapy, 
radiation, pleural 
sclerotherapy
Alive at 28 mths, but with 
progressive disease
10 2006 25 60/F Chest wall 6 mths Not Reported Not Reported Peritoneal Not Chemotherapy Not Reported
Table 1.  Details of reported cases of cutaneous metastases of malignant mesothelioma
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11 2007 12 67/M Lip, scalp 12 years Calretinin, CK5/6, 
CK7, EMA, HBME-
1
TTF-1 Pleural Epithelioid Chemotherapy 
(pemetrexed, cisplatin, 
gemcitabine)
Alive at 31 mths, but with 
progressive disease
12 2007 12 77/M Lip At time of 
biopsy
Calretinin, 
Cytokeratin (CAM 
5.2, AE1/AE3), CK7
BerEP4 Pleural Epithelioid Not Reported Deceased within 6 mths
13 2007 20 47/M Scalp, finger Not Reported Calretinin, CK5/6, 
Vimentin
Not Reported Pleural Biphasic Chemotherapy (3 cycles 
vinorelbine before 
stopping treatment due 
progressive disease)
Deceased within 6 mths
14 2009 18 61/M Face, 
posterior 
auricular
4 years Calretinin (focally), 
Vimentin, CD10, 
Cytokeratin (CAM 
5.2), SMA (focally)
CEA, TTF-1 Pleural Sarcomatoi
d
Chemotherapy (6 
cycles: pemetrexed, 
cisplatin), Radiotherapy
>37 mths disease free
15 2009 19 54/M Scalp 8 mths Calretinin, CK5/6 Not Reported Pleural Epithelioid* Chemotherapy 
(pemetrexed, cisplatin 
x5 mths)
Not Reported
16 2009 8 65/M Face, scalp, 
trunk
At time of 
diagnosis
Cytokeratin 
(MNF116), 
Vimentin
CEA, CD31, 
CD34, S100
Pleural Biphasic Not Reported Deceased shortly after 
biopsy
17 2010 26 72/M Abdomen At time of 
biopsy
Calretinin, Pan-
cytokeratin, WT1, 
CK7, CK20 (focal, 
weak)
B72.3, CDX2, 
Hep Par1, S100, 
MART-1, HMB-
45, PAX2
Peritoneal Epithelioid Not Reported Deceased shortly after 
biopsy
18 2011 27 75/M Chest wall 8 mths Calretinin, pan-
cytokeratin, 
CK5/6, 
thrombomodulin, 
vimentin, HMBE-1, 
EMA, WT1, BerEP4
CEA, B72.3, 
MOC-1, SMA, 
CA125
Pleural Epithelioid Chemoradiation Deceased within 19 mths
19 2013 2 55/M Abdominal 
wall
At time of 
biopsy
Calretinin, CK5/6, 
CK7, WT1
TTF-1, EA, 
Napsin
Pleural Epithelioid Chemotherapy (6 
cycles: pemetrexed, 
cisplatin)
Not Reported
20 Current 
Case (2017)
75/M Upper back 4 mths Calretinin, CK5/6, 
CK7, D2-40
TTF-1, CK20, 
Glut-1, PSA
Pleural Epithelioid Not Reported Deceased within a week 
following
cutaneous biopsy
Abbreviations: EMA, Epithelial Membrane Antigen; SMA, Smooth Muscle Actin; WT, Wilms' Tumor; CEA, Carcinoembryonic Antigen; UE, Ulex Europaeus lectin; HMB, Human 
Melanoma Black; MART, Melanocytic Antigen Recognized by cytotoxic T lymphocytes; TTF, Thyroid Transcription 
Factor; CDX, Caudal-related homeobox gene; PAX, Paired-box; CA, Cancer Antigen; PSA, Prostate-Specific Antigen; MTX, methotrexate; FU, fluorouracil
*Subtype was inferred based on histologic description
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